Journal article
Three-month stability of the cogstate brief battery in healthy older adults, mild cognitive impairment, and alzheimer's disease: Results from the Australian imaging, biomarkers, and lifestyle-rate of change substudy (AIBL-ROCS)
YY Lim, J Jaeger, K Harrington, T Ashwood, KA Ellis, A Stöffler, C Szoeke, R Lachovitzki, RN Martins, VL Villemagne, A Bush, CL Masters, CC Rowe, D Ames, D Darby, P Maruff
Archives of Clinical Neuropsychology | OXFORD UNIV PRESS | Published : 2013
Abstract
Large prospective studies of Alzheimer's disease (AD) have sought to understand the pathological evolution of AD and factors that may influence the rate of disease progression. Estimates of rates of cognitive change are available for 12 or 24 months, but not for shorter time frames (e.g., 3 or 6 months). Most clinical drug trials seeking to reduce or modify AD symptoms have been conducted over 12-or 24-week periods. As such, we aimed to characterize the performance of a group of healthy older adults, adults with amnestic mild cognitive impairment (aMCI), and adults with AD on the CogState battery of tests over short test-retest intervals. This study recruited 105 healthy older adults, 48 adu..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
Funding for the study was provided by AstraZeneca Pharmaceuticals LP, the CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF) in partnership with Edith Cowan University (ECU), Mental Health Research institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, CogState Ltd, Hollywood Private Hospital, Sir Charles Gardner Hospital. The study also receives funding from the National Health and Medical Research Council (NHMRC), the Dementia Collaborative Research Centres program (DCRC), The McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria.